



**ASX RELEASE**  
**25 February 2013**

## **Tissue Therapies Limited Announces Capital Raising of up to A\$13.2m**

- **A\$8.7m Placement completed**
- **A\$4.5m 1-for-10 non-renounceable Rights Issue**
- **Strong support from existing shareholders and new international and domestic institutional investors**
- **Provides the Company with funding to advance commercialisation of VitroGro<sup>®</sup> ECM**

Tissue Therapies Limited (“**Tissue**”) today announces a capital raising of up to A \$13.2m at an offer price of A\$0.21 per new fully paid ordinary share, consisting of a:

- A\$8.7m placement to professional and sophisticated investors (“Placement”)
- A\$4.5m 1-for-10 non-renounceable rights issue to existing shareholders (“Rights Issue”) (together “**the Offer**”)

The Company Chairman, Roger Clarke said, “The Placement gathered significant interest from international and sophisticated investors and was heavily oversubscribed. It was also gratifying to see a number of the Company’s long-term supporters participate. In the current market, it is certainly pleasing to see such solid, practical support for Tissue Therapies.”

Managing Director, Steven Mercer stated, “The funds raised will put TIS in a strong position to simultaneously prepare for and execute an expanded and accelerated sales launch program within the EU as well as internationally while also accelerating reimbursement approvals that will maximise market access.”

“We will also push ahead with gaining FDA approval for the human trials of VitroGro<sup>®</sup> ECM for the treatment of diabetic and venous ulcers.”

Bell Potter Securities Limited and RBS Morgans Corporate Limited acted as Joint Lead Managers to the Offer.

### **Placement**

The Placement was conducted within the 25% placement capacity of the Company in accordance with ASX L.R 7.1 & 7.1A, as approved at the Company’s Annual General Meeting (“AGM”) on 12 November 2012. New Shares under the Placement will rank *pari passu* with existing ordinary shares. Placement shares will also be eligible to participate in the Rights Issue.

Tissue Therapies Limited ABN 45 101 955 088 [www.tissuetherapies.com](http://www.tissuetherapies.com)  
Level 19, 179 Turbot Street, Brisbane QLD 4000 Australia  
GPO Box 1596, Brisbane QLD 4001  
telephone +61 7 3334 3900 facsimile +61 7 3334 3999

## Rights issue

Tissue intends to conduct a non-renounceable rights issue, to provide eligible Tissue shareholders with the opportunity to acquire 1 new share for every 10 existing shares held, at A\$0.21 per new share, to raise approximately A\$4.5 million. Eligible shareholders will also be able to apply for additional shares beyond their entitlement in the top-up facility available under the rights issue.

Eligible shareholders are expected to be those shareholders, at 7.00pm (AEDT) on the record date of Thursday, 7 March 2013, with a registered address in Australia and New Zealand.

Further details on the rights issue will be released in due course.

## Timetable

Event	Date
Tissue shares recommence trading on the ASX	Monday 25 February, 2013
Settlement of Placement	Friday 1 March, 2013
Trading of new shares issued under the Placement begins on ASX	Monday 4 March, 2013
Record date for eligibility in the Rights Issue	Thursday 7 March, 2013
Rights Issue opens	Tuesday 12 March, 2013
Offer booklet dispatched to shareholders	Tuesday 12 March, 2013
Rights Issue closes	Tuesday 26 March, 2013
Trading of new shares issued under the Rights Issue begins on ASX	Friday 5 April, 2013

## Shareholder Enquiries:

The Offer information line will be open on 12 March 2013, when the Information Booklet and Acceptance Form are despatched:

**Australian Shareholders: 1300 857 499**  
**New Zealand Shareholders: +61 2 8280 7753**

## | What is VitroGro<sup>®</sup> ECM

- VitroGro<sup>®</sup> ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro<sup>®</sup> ECM replaces the degraded matrix of a hard to heal wound. VitroGro<sup>®</sup> ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration <sup>[1]</sup>.
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process <sup>[1,2,3,4]</sup>. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds <sup>[1]</sup>. VitroGro<sup>®</sup> ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modeling indicates that VitroGro<sup>®</sup> ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

## **About Tissue Therapies Limited**

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro<sup>®</sup> ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)